View in EDS

Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer

Saved in:
Bibliographic Details
Title: Safety results from a phase III study (TURANDOT trial by CECOG) of first-line bevacizumab in combination with capecitabine or paclitaxel for HER-2-negative locally recurrent or metastatic breast cancer
Authors: Lang, I.1 lang@oncol.hu, Inbar, M.J.2, Kahán, Z.3, Greil, R.4, Beslija, S.5, Stemmer, S.M.6, Kaufman, B.7, Zvirbule, Z.8, Steger, G.G.9, Messinger, D.10, Brodowicz, T.9,11, Zielinski, C.9,11
Source: European Journal of Cancer. Nov2012, Vol. 48 Issue 17, p3140-3149. 10p.
Database: Academic Search Ultimate
Be the first to leave a comment!
You must be logged in first